Edition:
United Kingdom

Agios Pharmaceuticals Inc (AGIO.OQ)

AGIO.OQ on NASDAQ Stock Exchange Global Select Market

52.37USD
14 Dec 2017
Change (% chg)

$-2.63 (-4.78%)
Prev Close
$55.00
Open
$55.11
Day's High
$55.11
Day's Low
$52.23
Volume
177,866
Avg. Vol
143,840
52-wk High
$72.66
52-wk Low
$39.25

Select another date:

Mon, Dec 11 2017

BRIEF-Agios Pharmaceuticals Presents New Safety Data From Study on Leukemia Drug

* PRESENTS NEW SAFETY DATA FROM PHASE 1 EXPANSION STUDY EVALUATING ORAL IVOSIDENIB IN PATIENTS WITH R/R AML AND IDH1 MUTATION

Promising responses seen with Agios leukemia drug in study

Nearly a third of patients with an advanced form of a fast-progressing leukemia who carry a specific genetic mutation experienced a complete or near complete response to an experimental Agios Pharmaceuticals drug, according to data from an early stage trial released on Monday.

Promising responses seen with Agios leukemia drug in study

Dec 11 Nearly a third of patients with an advanced form of a fast-progressing leukemia who carry a specific genetic mutation experienced a complete or near complete response to an experimental Agios Pharmaceuticals drug, according to data from an early stage trial released on Monday.

BRIEF-Agios Pharmaceuticals Files For Potential Mixed Shelf Offering

* AGIOS PHARMACEUTICALS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text: (http://bit.ly/2yOMDeC) Further company coverage:

BRIEF-Agios presents updated phase 1 data from dose expansion cohort of ivosidenib

* Agios presents updated phase 1 data from dose expansion cohort of ivosidenib (AG-120) in patients with IDH1 mutant positive glioma

BRIEF-Agios reports Q3 revenue $11.4 million

* Agios Pharmaceuticals Inc - Qtrly ‍net loss per share $1.59 Source text for Eikon: Further company coverage:

BRIEF-Agios posts Q2 loss per share $1.78‍​

* Agios Pharmaceuticals Inc - ‍collaboration revenue was $11.3 million for quarter ended June 30, 2017, compared to $7.0 million for comparable period in 2016​

BRIEF-Agios Pharma says FDA approves Idhifa for treating relapsed/refractory Acute Myeloid Leukemia

* FDA grants approval of Idhifa, the first oral targeted therapy for adult patients with relapsed/refractory acute myeloid leukemia and an IDH2 mutation Source text for Eikon: Further company coverage:

FDA approves leukemia treatment developed by Celgene, Agios

Aug 1 The U.S. Food and Drug Administration (FDA) on Tuesday approved Celgene Corp and Agios Pharmaceuticals Inc's treatment for acute myeloid leukemia (AML) patients with a specific genetic mutation.

Select another date: